Reverse-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
| Property | Value | Notes |
|---|---|---|
| Purity determination | Reversed-phase HPLC | UV detection commonly at 214 nm |
| Mass confirmation | Mass spectrometry | Compared against theoretical 888.5 Da |
| Powder storage | -20 C or below | Dry and protected from light |
| Reconstituted storage | Aliquoted and frozen | Avoid repeated freeze-thaw cycles |
| Reconstitution solvent | Sterile water or neutral buffer | Avoid extreme pH conditions |
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
=== Paleontology === Although the word dinosaur can be used pejoratively to describe something that is becoming obsolete due to failing to adapt to changing conditions, non-avian dinosaurs did not become extinct due to being generally maladapted or unable to cope with normal climatic change, a view found in many older textbooks. Moreover, not all dinosaurs are extinct (see below). Dinosaurs are not extinct, as birds are classified within the theropod dinosaur lineage. The word dinosaur is commonly used to refer only to non-avian dinosaurs, reflecting an outdated conception of the ancestry of avian dinosaurs, the birds. The evolutionary origin of birds was an open question in paleontology for over a century, but the modern scientific consensus is that birds evolved from small feathered theropods in the Jurassic. Not all dinosaur lineages were cut short at the end of the Cretaceous during the Cretaceous–Paleogene extinction event, and over 11,000 species of avian theropods survive as part of the modern fauna. Dinosaurs, pterosaurs, and ichthyosaurs were not cold-blooded. Dinosaur thermoregulation is a topic of ongoing study. However, their high growth rates and the presence of dinosaur fossils in cold polar climates make cold-bloodedness implausible. Pterosaurs are inferred to be warm-blooded because they had a hair-like body covering, a trait absent in modern cold-blooded animals. Estimates of ichthyosaur body temperature are similar to marine mammals in every climate.
In February 2018, The Marshall Project published an investigation reporting that the new label allowed Johnson & Johnson to market Invega Sustenna as a way to keep people out of prison or jail. John Snook, executive director of the Treatment Advocacy Center, described the "stay-out-of-jail" marketing approach as a "depressing commentary" on the state of mental health treatment. Critics noted that the PRIDE study did not compare Invega Sustenna with other long-acting injectable antipsychotics, only with daily oral antipsychotics, and that the reduced rate of incarceration was likely due to improved drug adherence rather than a unique property of paliperidone palmitate. A 2022 review of internal pharmaceutical industry documents, published in the Journal of Correctional Health Care, identified Janssen as one of at least two companies that directly marketed antipsychotics to jails and prisons to increase sales. The review found that marketing strategies included targeted promotions, indirect "educational" advertising, and efforts to influence state formulary advisory boards. Concerns have also been raised about industry influence on the evidence base for long‑acting injectable (LAI) antipsychotics. In a 2024 paper in Accountability in Research, Lisa Cosgrove and colleagues presented a case analysis arguing that systematic reviews comparing LAIs to oral antipsychotics can be "shaped by commercial interests" and that financial conflicts of interest among review authors may "undermine patient‑centered models of recovery and care."
=== Bleeding disorders === Platelet-mimicking nanoparticles are under preclinical investigation for their potential to mitigate bleeding in conditions such as thrombocytopenia, coagulopathy, and von Willebrand disease. While pNPs had not previously been tested for congenital bleeding disorders, recent studies suggest their ability to enhance hemostasis in VWD type 2B and vWF-deficient conditions. In vitro experiments demonstrated that SP improved platelet recruitment and thrombus formation under thrombocytopenic and vWF-deficient conditions. In vivo studies further showed that pNPs reduced bleeding in VWD-2B mice and achieved near-complete hemostatic correction in vWF-knockout models, likely by providing a surface for platelet adhesion and fibrin deposition. The nanoparticles' stability, extended circulation time, and ability to be tailored with procoagulant molecules suggest their potential as a novel therapeutic approach for severe VWD and other bleeding disorders.
Sources: en.wikipedia.org
On 7 April 2023, Lula re-established the National Council for LGBTQIA+ Rights, a 38-member body of advisors charged with proposing policies and supporting campaigns aimed towards support for the LGBTQIA+ community in Brazil. The Ministry of Human Rights and Citizenship will be charged with funding for the council. The body previously existed from 2010 until the Bolsonaro presidency.
The "Cave with the Ring-Bearing Doves" (Cave 123) had a type of "central pillar" structure, with niche and circumambulating corridor, but with a very uncharacteristic cubic main cella crowned by a magnificent dome decorated with divinities. The main cella forms a square vestibule or main hall (3.42 x 3.42 meters; 12 x 12 feet) in front of the pillar forming the back wall, the vestibule being surmounted by a decorated dome. The prototype for the dome decorated with standing Buddhist deities is to be found in Group C of the caves at Bamiyan. It can also be seen in some other caves in the region, such as in Kumtura. The cave is named after a pattern of "flying geese holding a wreath" (or ring). This pattern is also known from Cave 69, which is dated to 625–647 CE because of the depiction and inscription of a historically identified king. Because of this marker, Cave 123 may be dated to the same period. Two monumental Buddha images occupy the sides of the main cella. They have full-body "mandorla" halos filled with a multitude of sitting or standing Buddhas. These monumental images represent the second Great Miracle of the Sakyamuni Buddha at Shravasti. The myriads of Buddhas emanating from him, each standing on a lotus, are a result of his deep meditation at Shravasti, as recounted in the Divyavadana. This understanding of the Great Miracle is most prominent among the Sarvastivadin and the Mulasarvastivadin. The two monumental Buddhas are surrounded by attendants, some light-skinned and some dark-skinned, and a Vajrapani.
Amanda Grace Paulovich is an oncologist, and a pioneer in proteomics using multiple reaction monitoring mass spectrometry to study tailored cancer treatment. Paulovich received a BS in Biological Sciences from Carnegie Mellon University in 1988, a PhD in Genetics from University of Washington in 1996, under the direction of Leland Hartwell. She also received a MD from University of Washington in 1998. Follow her residency in Internal Medicine at Massachusetts General Hospital, she also completed a Postdoctoral Fellowship in Computational Biology at the Massachusetts Institute of Technology Whitehead Center for Genomic Research in 2003, and a Fellowship in Medical Oncology at the Dana Farber Cancer Institute in 2004.
Sources: en.wikipedia.org
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.
Mass spectrometry is the usual confirmatory method because it measures the intact mass. Reversed-phase chromatography is used alongside it to estimate purity.
Not directly. Reported percentages depend on the chromatographic method, detection wavelength, and integration criteria, so the underlying method details matter.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.